Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.

Those differences did not reach statistical significance, and the overall annualized MI rates in RE-LY were <1% in all three treatment groups and comparable with those reported in numerous recent atrial fibrillation studies (0.55%–1.4%, Table 1 ). 3 – 11 No imbalances were seen between dabigatran and well-controlled warfarin (mean time in therapeutic ran

also in 111,027 other papers